Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 clinical trial trial evaluating the safety and efficacy of dronabinol (oral) for the treatment of obstructive sleep apnea

Trial Profile

A Phase 3 clinical trial trial evaluating the safety and efficacy of dronabinol (oral) for the treatment of obstructive sleep apnea

Planning
Phase of Trial: Phase III

Latest Information Update: 03 Jan 2019

At a glance

  • Drugs Dronabinol (Primary)
  • Indications Sleep apnoea syndrome
  • Focus Registrational; Therapeutic Use
  • Sponsors RespireRx Pharmaceuticals
  • Most Recent Events

    • 03 Jan 2019 RespireRx planning to proceed directly to a Phase 3 pivotal trial using the currently available dronabinol formulation (2.5, 5 and 10 mg gel caps)
    • 19 Jun 2018 According to a RespireRx Pharmaceuticals media release, subjects to the outcome of an intended meeting with the FDA, the company will be able to commence this trial.
    • 22 Jun 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top